Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Gasparini

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Neurobiology of Aging|December 29, 2009
Metabotropic glutamate receptor type 5 in levodopa-induced motor complicationsBazoumana Ouattara, Laurent Grégoire, Marc Morissette, et al.
Clinical Epigenetics|February 9, 2016
Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndromeSarah Brasa, Arne Mueller, Sébastien Jacquemont, et al.
Neuroimage|February 5, 2021
Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [<sup>11</sup>C]-ABP688 PET imaging in healthy volunteersJohannes Streffer, Valerie Treyer, Alfred Buck, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 18, 2015
A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's diseaseRalf Reilmann, Marie-Laure Rouzade-Dominguez, Carsten Saft, et al.
Bioorganic & Medicinal Chemistry|March 14, 2007
Synthesis and preliminary pharmacological evaluation of the four stereoisomers of (2S)-2-(2'-phosphono-3'-phenylcyclopropyl)glycine, the first class of 3'-substituted trans C1'-2'-2-(2'-phosphonocyclopropyl)glycinesMaura Marinozzi, Michaela Serpi, Laura Amori, et al.
Journal of Neuroinflammation|February 9, 2023
Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone modelNicolau Beckmann, Anna Neuhaus, Stefan Zurbruegg, et al.
Human Molecular Genetics|March 29, 2018
Protein synthesis levels are increased in a subset of individuals with fragile X syndromeSébastien Jacquemont, Laura Pacini, Aia E Jønch, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|October 11, 2017
Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging StudyChadi G Abdallah, Jonas Hannestad, Graeme F Mason, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|October 16, 2016
In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [<sup>11</sup>C]ABP688 and [<sup>18</sup>F]FPEBChristine DeLorenzo, Jean-Dominique Gallezot, John Gardus, et al.
Neurobiology of Disease|February 15, 2011
AFQ056, a new mGluR5 antagonist for treatment of fragile X syndromeJosien Levenga, Shigemi Hayashi, Femke M S de Vrij, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Neurobiology of Aging|December 29, 2009
Metabotropic glutamate receptor type 5 in levodopa-induced motor complicationsBazoumana Ouattara, Laurent Grégoire, Marc Morissette, et al.
Clinical Epigenetics|February 9, 2016
Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndromeSarah Brasa, Arne Mueller, Sébastien Jacquemont, et al.
Neuroimage|February 5, 2021
Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [<sup>11</sup>C]-ABP688 PET imaging in healthy volunteersJohannes Streffer, Valerie Treyer, Alfred Buck, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 18, 2015
A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's diseaseRalf Reilmann, Marie-Laure Rouzade-Dominguez, Carsten Saft, et al.
Bioorganic & Medicinal Chemistry|March 14, 2007
Synthesis and preliminary pharmacological evaluation of the four stereoisomers of (2S)-2-(2'-phosphono-3'-phenylcyclopropyl)glycine, the first class of 3'-substituted trans C1'-2'-2-(2'-phosphonocyclopropyl)glycinesMaura Marinozzi, Michaela Serpi, Laura Amori, et al.
Journal of Neuroinflammation|February 9, 2023
Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone modelNicolau Beckmann, Anna Neuhaus, Stefan Zurbruegg, et al.
Human Molecular Genetics|March 29, 2018
Protein synthesis levels are increased in a subset of individuals with fragile X syndromeSébastien Jacquemont, Laura Pacini, Aia E Jønch, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|October 11, 2017
Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging StudyChadi G Abdallah, Jonas Hannestad, Graeme F Mason, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|October 16, 2016
In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [<sup>11</sup>C]ABP688 and [<sup>18</sup>F]FPEBChristine DeLorenzo, Jean-Dominique Gallezot, John Gardus, et al.
Neurobiology of Disease|February 15, 2011
AFQ056, a new mGluR5 antagonist for treatment of fragile X syndromeJosien Levenga, Shigemi Hayashi, Femke M S de Vrij, et al.
Pageof 7